bioMérieux receives FDA Clearance for NEPHROCHECK® test on VIDAS®
bioMérieux receives FDA Clearance for NEPHROCHECK® test on VIDAS®
bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel
Marcy l’Étoile, France – bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® Joint Infection (JI) Panel has received De Novo authorization from the US Food and Drug Administration (FDA). This panel tests for 31 pathogens implicated in most acute joint infections, and also includes 8 antimicrobial resistance (AMR) […]
BioMérieux Joint Infection Panel Gets FDA De Novo Authorization
BioMérieux said on Wednesday that its BioFire Joint Infection (JI) Panel has received de novo authorization from the US Food and Drug Administration.
Biomerieux (BioFire) See Strong Q3 Growth
Biomerieux, which includes US-based BioFire, announced Q3 sales growth at 11.6%, significantly above expectations due, in part, to a strong upturn in US respiratory panels demand.
